Optibiotix Health Share Discussion Threads

[monkeywench1] 29/7/2018 09:18

Brilliant rampers.

[parob] 29/7/2018 09:16

As I mentioned the other day we haven't had a new commercial deal since the shackles have been off. Let's see what impact the next deal has. Every other deal has been sold into previously.Next news is getting closer.

[rafboy] 29/7/2018 09:16

I held 3 years ago and I won’t be selling my core holding for several years yet. We are just getting started for real.

[monkeywench1] 29/7/2018 09:08

Yeah best ramping thread ever.

[humphries1] 29/7/2018 09:07

shrewdmole me as well.
in my 20 years of investing i have never seen such a fantastic thread hats of to those who make it so

[shrewdmole] 29/7/2018 08:34

I can only say what I'm doing and I ain't selling a single share.

It doesn't mention either of the global sweetbiotix deals or any deals in detail.

I usually like her articles but huge lack of detail.

Let's face it she's saying too slice of you bought 3 years ago. It's been a long hold for many and things are just starting to get exciting. No mention of chairman buy or mikes tr1.

I'd rather back soh bullish recent interviews I think where he is starting to put values on things.

Just my opinion of course.

S

[plasybryn] 29/7/2018 08:25

Cautious investors take some profits. Wonder if that is a wise call?

[shrewdmole] 29/7/2018 08:11

Definite lack of detail

[oilchemist1] 29/7/2018 07:38

Mentioned in today's MOS
MIDAS UPDATE: OptiBiotix Health shares have tripled since 2015 hxxps://dailym.ai/2uXYK73 via hxxp://dailym.ai/android

[monkeywench1] 29/7/2018 07:34

How do know you have been my longest supporter??

[imnotlong] 28/7/2018 21:44

Sorry monkey. I have been your longest supporter.

But you are now filtered.

You really are strange.

[dire cons] 28/7/2018 21:22

Already filtered and sooo predictable that you don't even need to read. It's great. =~)

[shrewdmole] 28/7/2018 18:29

Just filter

[monkeywench1] 28/7/2018 14:15

Don't forget OptiRamp.

[speccy1] 28/7/2018 12:59

We sometimes forget amongst all the commercial deals, R&D continues.

We still have Optiscreen, so how long until the next discovery with a potential global market?

[slartybartfaster] 28/7/2018 12:22

Shrewdmole, didn't the interview suggest sweetbiotix has 12 more high level discussions? That is huge momentum right there.

[shrewdmole] 28/7/2018 11:19

Parob

The appointment of her as a director was a great move and possibly one forced by outside interest.

The contacts and previous appointments of most of the directors is very impressive and again you can only sit back and congratulate soh on his recruitment strategy.

Who will be sweetbiotix CEO?

Every time I read an article or hear an interview we go from lpldl being the big one to pharma being the big one to slimbiome then back to sweetbiotix.

The point I'm making is that each one is progressing and at a very good pace so I'd hate to guess which one ends up being the big one.
As much as a sugar replacement is seen as the holy grail, the other strains are equally exciting and we are yet to hear an update on pyschobiotics?!?! I doubt that's gone away as Opti like to progress things quietly.

One other thing to bear in mind is soh seems uber confident and he is usually very conservative but he can only tell us about certain deals. You can guarantee there will be numerous other deals and approaches being discussed.

S

[parob] 28/7/2018 08:14

This news is 3 weeks old now but was posted on the Optibiotix website this week under ‘Scientific Media’ with extra info on Sofia’s background. Interestingly she previously undertook contract work with Tate & Lyle. Those contacts could come in handy!

OptiBiotix appoints Dr Sofia Kolyda as new Director of Research and Development



Dr Sofia Kolyda has been appointed to the board of OptiBiotix Health, a world leader in the development of microbiome modulating products, as Director of Research & Development.

This appointment demonstrates OptiBiotix’s continued commitment to pioneering microbiome research and the development of innovative products to alleviate global health issues, such as obesity and high cholesterol. Dr Kolyda will take up her position with immediate effect.

Dr Kolyda was previously OptiBiotix’s Head of Research, and her expertise has been instrumental in the development of OptiBiotix’s technology through laboratory studies, human studies and manufacturing scale up. This has allowed the Company to create a rich pipeline of award-winning products, as well as winning best scientific publication at ProBiota in both 2017 and 2018.

OptiBiotix has established itself as a global leader in both targeted microbiome modulation, and the development of natural high intensity sweeteners and sweet healthy fibres (SweetBiotix®) as alternatives to sugar and existing artificial sweeteners. OptiBiotix’s strong science and deep pipeline of products has already led to agreements with a number of global corporates, including with Tata for its microbiome modulating cholesterol-reduction prebiotic (LPGOS), and two SweetBiotix® agreements, the first with one of the world’s largest suppliers of nutritional products and the second with one of the world’s largest providers of dairy products.

Given the high level of interest in OptiBiotix’s current products, particularly SweetBiotix®, and the potential for further partnerships, Dr Kolyda will take on responsibility for leading development programmes with current and future corporate partners.

Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to recognise the significant contribution Sofia has made in the development of OptiBiotix’s science into award winning products by offering her a position on the Board. Given the high level of interest we are seeing in our microbiome modulating and SweetBiotix® technologies, this appointment provides Board leadership to enable OptiBiotix to meet multiple partner needs and to fully exploit all opportunity in this area of growing industry and commercial interest.”

Prior to joining OptiBiotix, Dr Kolyda completed her PhD and was a post-doctoral research associate at the University of Reading’s Department of Food and Nutritional Sciences. During this time, she published numerous papers on the modulation of the human microbiome, as well as undertaking contract work for organisations such as GlaxoSmithKline PLC, Proctor & Gamble, and Tate & Lyle PLC.

[rafboy] 27/7/2018 22:36

Robo, hope it works out for you.

[judijudi] 27/7/2018 22:27

robo,
Stay here mate
Do not wander
imho

[robo28] 27/7/2018 21:55

Just wish I'd had that attitude at school, I just love learning and reading now, all my family and friends think I'm insane , but the more research I do /Elrico ya ha the more comfortable I feel about investing,

[monkeywench1] 27/7/2018 21:54

Is this a self help group now?